eFFECTOR Therapeutics, Inc.
EFTR · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.01 | 0.01 | -0.10 |
| FCF Yield | -115.96% | -148.17% | -7.45% | 9.19% |
| EV / EBITDA | -0.95 | -1.43 | 17.33 | 9.13 |
| Quality | ||||
| ROIC | -221.30% | -76.30% | -66.43% | 110.74% |
| Gross Margin | 0.00% | 98.51% | 98.32% | 100.00% |
| Cash Conversion Ratio | 0.83 | 1.14 | -1.58 | 0.97 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -56.10% | – | 3,475,926.64% |
| Free Cash Flow Growth | -13.63% | -4.66% | -282.22% | 149.57% |
| Safety | ||||
| Net Debt / EBITDA | -0.17 | -0.57 | -1.69 | -0.14 |
| Interest Coverage | 0.00 | -14.39 | -18.89 | 11.87 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | -1.96 | -0.24 | 0.00 |
| Cash Conversion Cycle | -7,661.71 | -10,416.94 | -9,342.81 | 0.00 |